Analysts move HubSpot 29 places higher in power ranking
Recursion Pharmaceuticals Inc RXRX
$3.74
▼ -3.86%
($-0.15)
🔥 High Short Interest
Open
$3.89
Prev Close
$3.89
Day Range
$3.70 – $3.90
52W Range
$2.77 – $7.18
Market Cap
$2.01B
Beta
1.20
EPS (TTM)
$-1.04
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-04-16 |
| Shares Out. | 529,910,000 |
| Website | recursion.com/ ↗ |
| Phone | 13026744089 |
| Employees | 600 |
| Revenue | $7.7M |
| Gross Profit | -$3.8M |
| Net Income | -$131.0M |
| Free Cash Flow | -$352.3M |
| Total Assets | $1.21B |
| Total Liabilities | $297.7M |
| Equity | $915.0M |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals Inc is a publicly traded company under the ticker symbol RXRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)
📰 Latest News for RXRX
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?